We just need your registered Email Id
to sent your password reset
instructions.
You're doing something extraordinary. We'll keep you in the loop with our latest news and special offers. Please update your profile on a regular basis and be an active community member. Let others know we exist and together we can move medicine forward.
You are now registered within Modern Trials network. If we receive patient inquires within your zip code we will let you know. Be on the look out for an E-Mail from our team.
| NCT Id | NCT04833517 |
|---|---|
| Title | Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study) |
| Condition | Prostate Cancer Metastatic |
| StudyType | Observational |
| Organization | Universität des Saarlandes |
| Sponsor/Collaborators | Universität des Saarlandes |
| Status | Recruiting |
| Gender | Male |
| AgeGroup | Adult Older Adult |
| Location (with distance) |
|
| Description | This prospective registry aims to assess outcome and toxicity of targeted radionuclide therapies in patients with advanced prostate cancer in clinical routine. While the major investigated treatment modality is prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, also other radionuclide therapies such as Ra223 and liver-directed radioembolization are included. The investigators believe that prospectively assessed long-term outcome data on implementation of radionuclide therapy, especially in the palliative setting of advanced mCRPC, help to better define the real benefits and risks of the respective treatment modalities for patients regarding survival and quality-of-life. |
Your interest has been recorded and our team is working hard for you. We will contact you with further steps.